Every Form 4 that Elanco Animal Health (ELAN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ELAN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELAN filings page.
Elanco Animal Health Inc. executive Robert M. VanHimbergen, the company’s EVP and CFO, reported buying 6,950 shares of common stock on December 11, 2025. The shares were purchased at a weighted average price of $21.6441 per share, with individual trades executed between $21.60 and $21.70 per share.
Following this transaction, he beneficially owns 124,233 shares of Elanco common stock held directly. The reported balance includes 7,426 shares that were previously reported but inadvertently omitted from his prior reported holdings.
Elanco Animal Health Inc. President, CEO and Director Jeffrey N. Simmons reported buying 22,000 shares of Elanco common stock on December 11, 2025. The shares were purchased in multiple transactions at a weighted average price of $21.7498 per share, with individual trade prices ranging from $21.739 to $21.75.
After this transaction, Simmons beneficially owned 167,000 shares held indirectly through a revocable trust and 1,802,380 shares held directly. The direct holdings include 1 share acquired on April 30, 2025 under Elanco Animal Health Inc.'s Employee Stock Purchase Plan.
Elanco Animal Health Inc. reported an insider equity transaction by its President, CEO and Director, Jeffrey N. Simmons. On 11/28/2025, Simmons acquired 119.0047 deferred stock units tied to Elanco common stock at a reference price of $23.27 per unit.
After this transaction, Simmons beneficially owned 18,474.9261 deferred stock units, held directly. Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent.
The units are part of the company’s Executive Deferral and Stock Match Plan and will settle in cash or shares after Simmons’ termination of employment or in a specified future year, according to the plan’s terms.
Elanco Animal Health executive Rajeev A. Modi reported an automatic award of deferred stock units tied to company stock. On 11/28/2025, he acquired 60.7916 deferred stock units at a reference price of $23.27. After this transaction, he beneficially owns 7,291.0368 derivative securities in the form of deferred stock units held directly.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units are scheduled to settle in cash or shares of common stock after Modi’s employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan. Modi serves as Executive Vice President U.S. Pet Health and Global Digital Transformation, and this filing reflects his ongoing equity-based compensation.
Elanco Animal Health Inc. director Kapila K. Anand reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, Anand acquired 10,314 shares of Elanco common stock at a stated price of $0, reflecting a board compensation grant rather than a market purchase. After this grant, Anand beneficially owned 94,973 shares of Elanco common stock in direct ownership. The filing notes that this grant is part of the standard annual equity award program for non-employee members of the company’s Board of Directors.
Elanco Animal Health Inc. director reports equity grant. A non-employee member of Elanco’s Board of Directors reported receiving a grant of 10,314 shares of common stock on 11/28/2025 as an annual equity award, structured as deferred stock units with a stated price of $0 for reporting purposes. Following this award, the director beneficially owns 12,853 shares of Elanco common stock in direct ownership. The transaction was reported on a Form 4 as a routine board compensation grant.
Elanco Animal Health Inc. director equity grant reported
A director of Elanco Animal Health Inc. reported receiving an annual equity award on 11/28/2025. The filing shows an award of 10,314 shares of common stock, recorded at a price of $0 as a grant of deferred stock units to a non-employee member of the Board of Directors. Following this grant, the director beneficially owns 88,714 shares of Elanco common stock in direct ownership. This is a routine Form 4 disclosure of director compensation in equity rather than a cash transaction.
Elanco Animal Health Inc. reported an equity award to one of its directors. On 11/28/2025, director Kirk P. McDonald received a grant of 10,314 shares of common stock in the form of deferred stock units as an annual equity award for non-employee board members, at a stated price of $0 per share.
Following this award, McDonald beneficially owns 88,714 shares of Elanco common stock in direct ownership. The filing reflects standard board compensation and does not describe any cash transaction for the company.
Elanco Animal Health Inc. director equity grant reported
A director of Elanco Animal Health Inc. reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, the reporting person acquired 10,314 shares of common stock at a stated price of $0, reflecting a board compensation grant rather than an open‑market purchase. Following this award, the director beneficially owned 121,773 shares of Elanco common stock in direct ownership. The grant is described as an annual equity award to each non‑employee member of the company’s board of directors.
Elanco Animal Health Inc. director equity grant reported
A director of Elanco Animal Health Inc. (ELAN) reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, the director acquired 10,314 shares of common stock at a stated price of $0, reflecting a board compensation grant rather than an open-market purchase. Following this transaction, the director beneficially owns 89,714 shares of Elanco common stock held directly.
The filing notes that this award is part of the regular annual equity compensation provided to non‑employee members of Elanco’s Board of Directors, aligning director pay with shareholder interests through stock-based compensation.
Elanco Animal Health Inc. director R. David Hoover reported an equity grant tied to his board service. On 11/28/2025, he received 10,314 shares of common stock as an annual equity award in the form of deferred stock units at a stated price of $0, reflecting a non-cash grant for a non-employee director. After this grant, he beneficially owns 106,773 shares of Elanco common stock directly and an additional 210,000 shares through a Revocable Trust and 15,920 shares through the Suzanne A. Hoover Revocable Trust. The filing is made as a Form 4 by a single reporting person in his capacity as a director.
Elanco Animal Health Inc. reported that a board director received an annual equity grant in the form of deferred stock units. On 11/28/2025, the director acquired 10,314 shares of common stock-equivalent deferred units at a stated price of $0 as an equity award for non-employee members of the Board of Directors. Following this grant, the director beneficially owns 84,813 shares of Elanco common stock in direct form. These awards align the director’s compensation more closely with long-term shareholder value through stock-based incentives.
Elanco Animal Health director reports equity grant
A director of Elanco Animal Health Inc. reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, the director acquired 10,314 shares of common stock at a reported price of $0, reflecting that this was an equity grant rather than an open‑market purchase. Following this transaction, the director beneficially owned 91,278 shares of Elanco common stock in direct ownership. The award is described as part of the regular annual equity compensation for non‑employee members of the company’s Board of Directors.
Elanco Animal Health Inc. (ELAN) reported an insider equity award for a member of its Board of Directors. On 11/28/2025, director Michael J. Harrington received 10,314 shares of common stock, recorded at a price of $0 per share, reflecting a grant rather than a market purchase. Following this transaction, he beneficially owned 109,577 shares of Elanco common stock in direct ownership. The company explains that this grant represents deferred stock units issued as an annual equity award to each non-employee member of the Board of Directors, aligning director compensation with shareholder interests through stock-based incentives.
Elanco Animal Health Inc. (ELAN) reported a Form 4 filing for executive officer Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation. On 11/14/2025, he acquired 67.0754 deferred stock units at a price of $21.09 per unit. Following this transaction, he beneficially owns 7,230.2452 deferred stock units, held directly.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. According to the company’s Executive Deferral and Stock Match Plan, these deferred stock units will settle in cash or shares after employment ends or in a specified future year.
Elanco Animal Health Inc. executive Jeffrey N. Simmons, the company’s President, CEO and Director, reported a new equity-related award. On 11/14/2025, he acquired 131.3058 deferred stock units at a reference price of $21.09 per unit. After this transaction, he beneficially owned 18,355.9214 derivative securities, held directly. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and these units are designed to settle in cash or shares following termination of employment or during a specified future year under the Executive Deferral and Stock Match Plan.
Elanco Animal Health (ELAN) reported that President, CEO and Director Jeffrey N. Simmons acquired 125.0221 deferred stock units on 10/31/2025 at $22.15 per unit. Following this transaction, he beneficially owns 18,224.6156 derivative securities, held as direct ownership.
Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent. These units settle in cash or shares following termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health (ELAN) officer Rajeev A. Modi reported a routine insider transaction on a Form 4. On 10/31/2025, he acquired 63.8655 Deferred Stock Units (DSUs) in a transaction coded “A.” Following this activity, he beneficially owned 7,163.1698 derivative securities, held directly. The filing lists a $22.15 price for the derivative security. Each DSU represents the right to receive one share of Elanco common stock or the cash equivalent, and DSUs settle in cash or shares following termination of employment or during a specified future year in accordance with the Executive Deferral and Stock Match Plan.
Elanco Animal Health (ELAN): CEO Form 4 filing. President, CEO and Director Jeffrey N. Simmons reported an acquisition of 129.2829 deferred stock units on 10/17/2025 (Transaction Code A). The filing shows a $21.42 price of the derivative security and a post‑transaction balance of 18,099.5935 deferred stock units held directly.
Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent. These units settle in cash or shares following termination of employment or during a specified future year in accordance with the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health (ELAN) reported an insider transaction by Executive Vice President Rajeev A. Modi. On 10/17/2025, he acquired 66.042 deferred stock units (DSUs) at $21.42, bringing his directly held DSUs to 7,099.3043.
Each DSU represents the right to receive one share of Elanco common stock or the cash equivalent. According to the company’s Executive Deferral and Stock Match Plan, DSUs settle in cash or shares following termination of employment or during a specified future year.
Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation at Elanco Animal Health Inc. (ELAN), reported a Section 16 transaction dated 10/03/2025. He acquired 68.5378 deferred stock units under the company's deferral plan at a reported price of $20.64 per share equivalent. Following the reported transaction, the filing shows 7,033.2623 shares of common stock beneficially owned. The deferred stock units represent the right to receive one share of common stock or the cash equivalent and will settle in cash or shares after termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan.
Jeffrey N. Simmons, President, CEO and Director of Elanco Animal Health Inc. (ELAN), reported on 10/03/2025 an acquisition of 134.1686 deferred stock units at an indicated price of $20.64. After the transaction, Mr. Simmons is recorded as beneficially owning 17,970.3106 shares (or share equivalents). The deferred stock units represent the right to receive one share each or the cash equivalent and will settle in cash or shares following termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan. The Form 4 was signed by an attorney-in-fact on 10/07/2025.
Elanco Animal Health Inc. (ELAN) reported insider awards to Executive Vice President and Chief Financial Officer Robert M. VanHimbergen. The Form 4 discloses a grant of 109,857 restricted stock units that vest in three equal tranches on July 7, 2026, July 7, 2027, and July 7, 2028. The filing also shows a grant of 53,869 employee stock options with an exercise price of $20.80, exercisable beginning in the same three-tranche schedule and expiring on October 1, 2035. Both holdings are reported as direct ownership following the transactions. The Form 4 was signed by an attorney-in-fact on behalf of Mr. VanHimbergen and lists the transaction date as October 1, 2025.
Jeffrey N. Simmons, President, CEO and Director of Elanco Animal Health Inc (ELAN), reported an acquisition of 144.2313 deferred stock units on 09/19/2025. Each deferred stock unit represents the right to one share of common stock or the cash equivalent and settles in cash or shares under the company’s Executive Deferral and Stock Match Plan. The reported transaction used transaction code A (acquisition) at an indicated underlying price of $19.20 per share, and following the transaction Mr. Simmons beneficially owns 17,836.142 shares directly. The Form 4 was signed on behalf of Mr. Simmons by Amy C. Seidel as attorney-in-fact on 09/23/2025.
Rajeev A. Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation at Elanco Animal Health Inc. (ELAN), acquired 73.6781 deferred stock units on 09/19/2025 under the companys Executive Deferral and Stock Match Plan. Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent, and such units settle in cash or shares following termination of employment or in a specified future year. After the reported transaction Mr. Modi beneficially owned 6,964.7245 units (directly).
The units were reported with an indicated price of $19.20 per underlying share. The filing was signed by an attorney-in-fact on behalf of Mr. Modi and notes his officer role; no other material transactions or additional context are included.